liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Priming with r-metHuSCF and filgrastim or chemotherapy and filgrastim in patients with malignant lymphomas: a randomized phase II pilot study of mobilization and engraftment
Aarhus University Hospital.
Rigshosp, Copenhagen, Denmark .
University Hospital, Helsinki.
Turku University Hospital.
Show others and affiliations
2011 (English)In: BONE MARROW TRANSPLANTATION, ISSN 0268-3369, Vol. 46, no 1, 44-51 p.Article in journal (Refereed) Published
Abstract [en]

SCF has been shown to synergize with G-CSF to mobilize CD34(+) PBPCs. In this study we report results from this combination after a phase II trial of 32 patients with malignant lymphoma randomized to receive recombinant methionyl human SCF (ancestim, r-metHuSCF) in combination with recombinant methionyl human G-CSF (filgrastim, r-metHuG-CSF) (experimental arm A) or routine chemotherapy plus filgrastim (conventional arm B). The primary objective was to evaluate the side effects and toxicity during priming and mobilization. The secondary objectives were efficacy by the level of blood-circulating PBPCs, the number of harvest days and the time to three-lineage engraftment after autografting. First, during priming 5 patients had 8 serious events, 4 in each arm. A summary of all adverse events revealed 30 (94%) patients suffering from 132 events of all grading. Second, neutropenia and thrombocytopenia was documented in arm B. Third, 9/14 (64%) patients in arm A reached the target of 5 million CD34(+) cells/kg body weight (bw) compared with 13/15 (87%) in arm B. The results represent the first randomized trial of growth factor plus chemotherapy priming and indicate that a formal phase III trial very unlikely may challenge chemotherapy plus r-metHuG-CSF priming in candidates for high-dose therapy.

Place, publisher, year, edition, pages
Nature Publishing Group , 2011. Vol. 46, no 1, 44-51 p.
Keyword [en]
SCF, priming, mobilization, lymphoma, clinical trial
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-65568DOI: 10.1038/bmt.2010.84ISI: 000286136000010OAI: oai:DiVA.org:liu-65568DiVA: diva2:396784
Available from: 2011-02-11 Created: 2011-02-11 Last updated: 2011-02-11

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Juliusson, Gunnar

Search in DiVA

By author/editor
Juliusson, Gunnar
By organisation
OncologyFaculty of Health SciencesDepartment of Haematology UHL
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 44 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf